Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy
Author:
Affiliation:
1. Janssen Research & Development Beerse Belgium
2. Janssen Biopharma Inc South San Francisco CA USA
3. Janssen Pharmaceuticals Research & Development Titusville FL USA
Funder
Janssen Pharmaceuticals
Publisher
Wiley
Subject
Virology,Infectious Diseases,Hepatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13351
Reference33 articles.
1. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
3. New therapeutic agents for chronic hepatitis B
4. Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
5. Small-Molecule Effectors of Hepatitis B Virus Capsid Assembly Give Insight into Virus Life Cycle
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Design, synthesis, and structure-activity relationship of a bicyclic HBV capsid assembly modulator chemotype leading to the identification of clinical candidate AB-506;Bioorganic & Medicinal Chemistry Letters;2023-10
2. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial;The Lancet Gastroenterology & Hepatology;2023-09
3. Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study;Antiviral Research;2023-08
4. Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment;The Journal of Clinical Pharmacology;2023-03-20
5. Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB ‐506 from Phase 1 studies in healthy subjects and those with hepatitis B;Hepatology Communications;2022-10-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3